Understanding this mechanism helps individuals and healthcare providers address constipation associated with GLP-1 therapies more effectively, tailoring interventions to support digestive health during the weight loss journey
Retatrutide has shown the highest weight loss numbers in trials so far (28.7% in Phase 3 TRIUMPH-4 vs 22.5% for tirzepatide in SURMOUNT-1 and 15.8% for semaglutide in STEP-1)
Retatrutide is not currently FDA-approved as a prescription weight-loss medication
We provide secure and discreet shipping throughout the United Kingdom and selected European destinations
90 When combined with treatments such as micronutrient mesotherapy or HA fillers, CaHA shows potential synergistic effects, enhancing skin firmness, luminosity, pigmentation, and volume restoration
These numbers explain why so many patients either give up on treatment or turn to compounded alternatives and discount programs